Short Interest in Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Grows By 57,950.0%

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) saw a significant growth in short interest in July. As of July 15th, there was short interest totaling 1,161 shares, a growth of 57,950.0% from the June 30th total of 2 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average trading volume of 3,040 shares, the short-interest ratio is presently 0.4 days.

Enzon Pharmaceuticals Stock Performance

Shares of OTCMKTS:ENZN opened at $4.35 on Friday. Enzon Pharmaceuticals has a 1 year low of $1.50 and a 1 year high of $9.50. The firm has a fifty day moving average price of $5.19 and a 200 day moving average price of $5.71. The company has a current ratio of 2.01, a quick ratio of 1.16 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $3.23 million, a PE ratio of -0.64 and a beta of -0.05.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last announced its quarterly earnings results on Monday, May 4th. The biotechnology company reported ($0.84) earnings per share for the quarter. The business had revenue of $86.54 million during the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.